NASDAQ:LOANManhattan Bridge Capital Stock Price, Forecast & News

Manhattan Bridge Capital's stock was trading at $5.08 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, LOAN shares have decreased by 14.2% and is now trading at $4.36. View which stocks have been most impacted by Coronavirus.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Manhattan Bridge Capital in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Manhattan Bridge Capital.

Manhattan Bridge Capital is scheduled to release its next quarterly earnings announcement on Friday, July 24th 2020. View our earnings forecast for Manhattan Bridge Capital.

Manhattan Bridge Capital Inc. (NASDAQ:LOAN) posted its quarterly earnings results on Monday, April, 13th. The credit services provider reported $0.11 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $0.11. The credit services provider had revenue of $1.71 million for the quarter. Manhattan Bridge Capital had a return on equity of 13.40% and a net margin of 60.44%. View Manhattan Bridge Capital's earnings history.

Manhattan Bridge Capital declared a quarterly dividend on Thursday, May 7th. Shareholders of record on Friday, July 10th will be given a dividend of $0.10 per share on Wednesday, July 15th. This represents a $0.40 dividend on an annualized basis and a dividend yield of 9.17%. The ex-dividend date is Thursday, July 9th. View Manhattan Bridge Capital's dividend history.

2 brokers have issued 1-year price objectives for Manhattan Bridge Capital's shares. Their forecasts range from $6.00 to $6.00. On average, they expect Manhattan Bridge Capital's share price to reach $6.00 in the next twelve months. This suggests a possible upside of 37.6% from the stock's current price. View analysts' price targets for Manhattan Bridge Capital.

Media headlines about LOAN stock have been trending extremely negative recently, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Manhattan Bridge Capital earned a media sentiment score of -4.0 on InfoTrie's scale. They also assigned media headlines about the credit services provider a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the next several days. View the latest news aboutManhattan Bridge Capital.

Manhattan Bridge Capital saw a drop in short interest in the month of May. As of May 15th, there was short interest totaling 7,300 shares, a drop of 19.8% from the April 30th total of 9,100 shares. Based on an average daily trading volume, of 53,700 shares, the days-to-cover ratio is currently 0.1 days. Currently, 0.1% of the company's stock are short sold. View Manhattan Bridge Capital's Current Options Chain.

Some companies that are related to Manhattan Bridge Capital include Bluerock Residential Growth REIT Inc Class A (NYSEAMERICAN) (BRG), CIM Commercial Trust (CMCT), Anworth Mortgage Asset Corp Reit (ANH), Cherry Hill Mortgage Investment (CHMI), Corenergy Infrastructure Trust (CORR), Clipper Realty (CLPR), Washington Prime Group (WPG), Drive Shack (DS), Ellington Residential Mortgage REIT (EARN), Braemar Hotels & Resorts (BHR), Western Asset Mortgage Capital (WMC), Postal Realty Trust (PSTL), Pennsylvania R.E.I.T. (PEI), Arlington Asset Investment (AI) and AG Mortgage Investment Trust (MITT). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Manhattan Bridge Capital investors own include Allena Pharmaceuticals (ALNA), Energy Transfer LP Unit (ET), NovaBay Pharmaceuticals (NBY), NovaBay Pharmaceuticals (NBY), AcelRx Pharmaceuticals (ACRX), Actinium Pharmaceuticals (ATNM), Dynex Capital (DX), Rigel Pharmaceuticals (RIGL), Saratoga Investment (SAR) and Two Harbors Investment (TWO).

Manhattan Bridge Capital trades on the NASDAQ under the ticker symbol "LOAN."

Manhattan Bridge Capital's stock is owned by many different retail and institutional investors. Top institutional investors include Shufro Rose & Co. LLC (1.19%), Hardy Reed LLC (0.76%), National Asset Management Inc. (0.59%), Advisor Group Holdings Inc. (0.12%) and Acadian Asset Management LLC (0.07%). Company insiders that own Manhattan Bridge Capital stock include Assaf Ran, Eran Goldshmit, Lyron L Bentovim and Vanessa Kao. View institutional ownership trends for Manhattan Bridge Capital.

LOAN stock was purchased by a variety of institutional investors in the last quarter, including Hardy Reed LLC, Advisor Group Holdings Inc., Acadian Asset Management LLC, National Asset Management Inc., and Shufro Rose & Co. LLC. Company insiders that have bought Manhattan Bridge Capital stock in the last two years include Assaf Ran, and Vanessa Kao. View insider buying and selling activity for Manhattan Bridge Capital.

Shares of LOAN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of LOAN stock can currently be purchased for approximately $4.36.

Manhattan Bridge Capital has a market capitalization of $41.99 million and generates $7.34 million in revenue each year. The credit services provider earns $4.49 million in net income (profit) each year or $0.47 on an earnings per share basis. Manhattan Bridge Capital employs 4 workers across the globe.

The official website for Manhattan Bridge Capital is www.manhattanbridgecapital.com.

Manhattan Bridge Capital's mailing address is 60 CUTTER MILL RD. SUITE 205, GREAT NECK NY, 11021. The credit services provider can be reached via phone at 516-444-3400.